Importancia del calcio en mujeres peri y posmenopáusicas ...

20. National Institutes of Health. NIH Consensus Development
Panel on Optimal Calcium Intake. Optimal calcium intake.
JAMA 1994;272:1942-8.
21. Recker R, Lappe J, Davies KM, Heaney R. Bone remodeling
increases substantially in the years after menopause and
remains in older osteoporosis patients. J Bone Miner Res
2004;19:1628-33.
22. Recker RR, Lappe J, Davies K, Heaney R. Characterization of
perimenopausal bone loss: a prospective study. J Bone Miner
Res 2000;15:1965-73.
23. The North American Menopause Society. The management of
osteoporosis in postmenopausal women: 2006 position statement
of The North American Menopause Society. Menopause
2006;13:340-67.
24. Aloia JF, Vaswani A, Yeh JK, Ross PL, Flaster E, Dilmanian
FA. Calcium supplementation with and without hormone replacement
therapy to prevent postmenopausal bone loss. Ann
Intern Med 1994;120:97-103.
25. Chevalley T, Rizzoli R, Nydeggar V, et al. Effects of calcium
supplements on femoral bone mineral density and vertebral
fracture rate in vitamin-D-replete elderly patients. Osteoporos
Int 1994;4:245-52.
26. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled
trial of the effect of calcium supplementation on bone density
in postmenopausal women. N Engl J Med 1990;323:878-
83.
27. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of
calcium and vitamin D supplementation on bone density in
men and women 65 years of age and older. N Engl J Med
1997;337:670-6.
28. Devine A, Dick IM, Heal SJ, Criddle RA, Prince RL. A 4-year
follow-up study of the effects of calcium supplementation on
bone density in elderly postmenopausal women. Osteoporos
Int 1997;7:23-28.
29. Elders PJ, Netelenbos JC, Lips P, et al. Calcium supplementation
reduces vertebral bone loss in perimenopausal women:
a controlled trial in 248 women between 46 and 55 years of
age. J Clin Endocrinol Metab 1991;73:533-40.
30. Peacock M, Liu G, Carey M, et al. Effect of calcium or 25OH
vitamin D3 dietary supplementation on bone loss at the hip in
men and women over the age of 60. J Clin Endocrinol Metab
2000;85:3011-9.
31. Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional
deficiency prevents spine fractures in elderly women.
J Bone Miner Res 1996;11:1961-6.
32. Reid JR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect
of calcium supplementation on bone loss in postmenopausal
women. N Engl J Med 1993;328:460-4.
33. Riggs BL, O’Fallon WM, Muhs J, O’Connor MK, Kumar R,
Melton LJ III. Long-term effects of calcium supplementation
on serum parathyroid hormone level, bone turnover, and bone
loss in elderly women. J Bone Miner Res 1998;13:168-74.
34. Elders PJ, Lips P, Netelenbos JC, et al. Long-term effect of
calcium supplementation on bone loss in perimenopausal
women. J Bone Miner Res 1994;9:963-70.
35. Reid JR, Ames RW, Evans MC, Gamble GD, Sharpe SJ.
Longterm effects of calcium supplementation on bone loss and
fractures in postmenopausal women: a randomized controlled
trial. Am J Med 1995;98:331-5.
36. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and cal-
Revista del climaterio Volumen 10, Núm. 58, mayo-junio, 2007
Importancia del calcio en mujeres peri y posmenopáusicas
cium to prevent hip fractures in elderly women. N Engl J Med
1992;327:1637-42.
37. Porthouse J, Cockayne S, King C, et al. Randomized controlled
trial of calcium and supplementation with cholecalciferol
(vitamin D3) for prevention of fractures in primary care. BMJ
2005;330:1003-9.
38. Grant AM, Avenell A, Campbell MK, et al, for the RECORD
Trial Group. Oral vitamin D3 and calcium for secondary prevention
of low-trauma fractures in elderly people (Randomized
Evaluation of Calcium Or vitamin D, RECORD): a randomized
placebo-controlled trial. Lancet 2005;365:1621-8.
39. Jackson RD, LaCroix AZ, Gass M, et al, for the Women’s Health
Initiative Investigators. Calcium plus vitamin D supplementation
and the risk of fractures. N Engl J Med 2006;354:669-83.
40. Prince RL, Devine A, Dhaliwal SS, Dick IM. Effects of calcium
supplementation on clinical fracture and bone structure: results
of a 5-year, double-blind, placebo-controlled trial in elderly
women. Arch Intern Med 2006;166:869-75.
41. Specker BL. Evidence for an interaction between calcium intake
and physical activity on changes in bone mineral density.
J Bone Miner Res 1996;11:1539-44.
42. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates
the effect of estrogen and calcitonin on bone mass: review
and analysis. Am J Clin Nutr 1998;67:18-24.
43. Cummings SR, Black DM, Thompson DE, et al. Effect of
alendronate on risk of fracture in women with low bone density
but without vertebral fractures: results from the Fracture
Intervention Trial. JAMA 1998;280:2077-82.
44. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene
on bone mineral density, serum cholesterol concentrations,
and uterine endometrium in postmenopausal women.
N Engl J Med 1997;337:1641-7.
45. Evans RA, Somers NM, Dunstan CR, Royle H, Kos S. The effect
of low-dose cyclical etidronate and calcium on bone mass
in early postmenopausal women. Osteoporos Int 1993;3:71-
75.
46. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster
JY, for the BMD-MN Study Group. Risedronate reverses bone
loss in postmenopausal women with low bone mass: results
from a multinational, double-blind, placebo-controlled trial. J
Clin Endocrinol Metab 2000;85:1895-900.
47. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid
IR. The effect of the antiestrogen tamoxifen on bone mineral
density in normal late postmenopausal women. Am J Med
1995;99:636-41.
48. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of
established postmenopausal osteoporosis with raloxifene: a
randomized trial. J Bone Miner Res 1998;13:1747-54.
49. Meunier PJ, Vigno E, Garnero P, et al, for the Raloxifene
Study Group. Treatment of postmenopausal women with
osteoporosis or low bone density with raloxifene. Osteoporos
Int 1999;10:330-6.
50. Ryan PJ, Blake GM, Davie M, et al. Intermittent oral disodium
pamidronate in established osteoporosis: a 2 year doublemasked
placebo-controlled study of efficacy and safety. Osteoporos
Int 2000;11:171-76.
51. Sebaldt RJ, Ioannidis G, Adachi JD, et al. 36 month intermittent
cyclical etidronate treatment in patients with established corticosteroid
induced osteoporosis. J Rheumatol 1999;26:1545-
9.
153